ReWalk Robotics Reports Fourth Quarter and Full Year 2022 Financial Results

3 years ago

Strong Conclusion to 2022 – Q4’22 Revenue Highest Since Start of COVID-19 Pandemic Record Quarterly MyoCycle Sales Supplement Improved Exoskeleton…

One-in-five people in Canada have cut back on health-related expenses due to inflation

3 years ago

The latest TELUS Health Mental Health Index finds that one-third of people in Canada avoid interacting with others; financial pressure…

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

3 years ago

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million,…

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

3 years ago

NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced…

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application

3 years ago

PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the…

Agra Ventures Appoints Nick Kuzyk as Permanent Chief Executive Officer and Director

3 years ago

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF),…

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

3 years ago

Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for…

Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

3 years ago

CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.),…

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

3 years ago

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30…

Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027

3 years ago

LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering…